Westover Capital Advisors’s BioMarin Pharmaceuticals BMRN Stock Holding History

Westover Capital Advisors’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q2	–	Sell	-17,790	Closed	-$1.47M	–	79
2016 Q1	$1.47M	Sell	17,790 -1,674	-9%	-$136K	1.24%	32
2015 Q4	$2.04M	Sell	19,464 -298	-2%	-$31.1K	1.7%	22
2015 Q3	$2.08M	Sell	19,762 -706	-3%	-$94.3K	1.79%	21
2015 Q2	$2.8M	Sell	20,468 -1,353	-6%	-$168K	2.23%	16
2015 Q1	$2.72M	Sell	21,821 -66	-0.3%	-$6.99K	2.2%	14
2014 Q4	$1.98M	Sell	21,887 -1,724	-7%	-$143K	1.7%	23
2014 Q3	$1.7M	Buy	23,611 +5,562	+31%	+$366K	1.39%	28
2014 Q2	$1.12M	Buy	18,049 +1,496	+9%	+$90.4K	0.95%	41
2014 Q1	$1.13M	Hold	16,553	–	–	1.05%	37
2013 Q4	$1.17M	Buy	+16,553	New	+$1.12M	1.11%	36

Other funds holding BMRN

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Westover Capital Advisors's BMRN Position: Q2 2016 in Review

Westover Capital Advisors sold out of BioMarin Pharmaceuticals (BMRN) in Q2 2016, closing a stake of 17,790 shares — an estimated $1.47M sold.

Westover Capital Advisors first reported a position in BMRN in Q4 2013 and held it in 10 quarters. The position peaked at $2.8M in Q2 2015. 392 funds tracked by Wall St. Rank hold BMRN as of Q2 2016.

Westover Capital Advisors reported no remaining BioMarin Pharmaceuticals position as of Q2 2016 after selling out during the quarter.
Westover Capital Advisors sold 17,790 BioMarin Pharmaceuticals shares in Q2 2016, an estimated $1.47M.
Westover Capital Advisors first reported a position in BioMarin Pharmaceuticals in Q4 2013 and held it in 10 quarters.
Westover Capital Advisors's BioMarin Pharmaceuticals position peaked at $2.8M in Q2 2015.
392 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2016.

Based on Westover Capital Advisors's 13F filing for Q2 2016, filed 15 Aug 2016.